DDRi Summit 2025: Monitoring of DNA Damage Response Biomarkers using Circulating Tumour Cells captured with ANGLE’s Parsortix® instrument from Ovarian, Prostate, and Breast cancer patients
Digoxin for reduction of circulating tumour cell cluster size in metastatic breast cancer
CIRCUS: CIRCUlating tumour cells in soft tissue Sarcoma – a short report
AACR LBx 24 – Development of a scoring system to classify HER2 protein expression in Circulating Tumour Cells through immunofluorescence following isolation using Parsortix® instruments
DDR Conference – Detection of DNA Damage Response Biomarkers in Circulating Tumour Cells using ANGLE’s Parsortix® instrument and downstream immunofluorescence assays
Identification of circulating tumor cells captured by the FDA-cleared Parsortix® PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations
Prognostic significance of circulating tumor cells and tumor related transcripts in small cell lung cancer: A step further to clinical implementation
Plasminogen activator inhibitor 1 is associated with high-grade serous ovarian cancer metastasis and is reduced in patients who have received neoadjuvant chemotherapy
Targeting Translation and the Cell Cycle Inversely Affects CTC Metabolism but Not Metastasis
DanioCTC: Analysis of Circulating Tumor Cells from Metastatic Breast Cancer Patients in Zebrafish Xenografts